Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 20, 2008

Intas Biopharmaceuticals Acquires Biologics Process Development

  • Intas Biopharmaceuticals has acquired Biologics Process Development (BPD), based in Poway, California.  BPD provides contract laboratory services in molecular biology, recombinant protein purification and expression, cell culture, bacterial fermentation, cold and frozen cell/material storage, and consulting in biologics process scale-up.

    This acquisition will facilitate Intas Biopharma’s entry into the U.S. market especially in the area of biologics contract research and manufacturing services. Scott M. Brown, founder, president, and CSO of BPD, will stay on in his present role.

    Related Links:

    Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »